Genetic Alteration After Systemic Treatment in Breast Cancer

Samsung Medical Center

Status: Unknown

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT02591966

2014-11-015

Details and patient eligibility

About

The purpose of this study is to investigate effects of systemic treatments on genomic profiles in patients with breast cancer and to compare genomic profiling between premenopausal and postmenopausal women by systemic treatments in breast cancer.

Full description

Prospective single arm trial using three patients' cohorts. One-hundred patients for each cohort and a total of 300 patients (600 biopsy samples) will be entered to this trial.

The hypothesis is that genomic alterations measured by CancerSCAN and cfDNA, Whole exome sequencing (WES), Whole transcriptome sequencing (WTS), FACS(Fluorescence-Activated Cell Sorting), cytokine and immunologic signature analysis would be different between pre- and post-menopausal women and would be predictive biomarkers for each cohort according to pre- and post-menopausal status. Three groups of patients will be recruited:

1. The patients who receive neoadjuvant systemic treatments:
2. The patients who have distant metastatic sites at first and recur from surgery:
3. The patients who are going to receive first-line chemotherapy

Enrollment: 350 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients older than 20 years

2. Patients with histologically confirmed breast cancer at three disease status

   • Patients who are going to receive neoadjuvant chemotherapy with feasible biopsy site.
   • Patients who recur from curative surgery and have distant metastasis with feasible biopsy site. ; Patients must have received adjuvant chemotherapy after curative surgery.
   • Patients who are going to first-line palliative chemotherapy with feasible biopsy site.

3. Patients with PS ECOG 0 - 2

4. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.

5. Written informed consent form

6. Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to study as defined below:

   • Haemoglobin ≥9.0 g/L (transfusion allowed)
   • White blood cells (WBC) > 3 x 109/L
   • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
   • AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN

Exclusion criteria

1. Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical condition that would interfere with the subject's safety.
2. Double primary cancer (except for any cancer in remission for > 5 years, cervix cancer in situ, basal cell cancer in situ, any in situ cancers that are resected)

Trial design

350 participants in 1 patient group

Biomarker group

Description:

1. The patients who receive neoadjuvant systemic treatments: 2. The patients who have distant metastatic sites at first and recur from surgery: 3. The patients who are going to receive first-line chemotherapy: